Skip to content

Author

N. Gagelmann

We have 5 of 184 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse and improved survival.

Germline DDX41 variants are a recognized cause of adult myelodysplastic neoplasms (MDS), characterized by distinct biological features and favorable prognosis. The independent effect of DDX41 status on outcomes after allogeneic transplantation, the role of conditioning intensity, and treatment-related toxicity risk rem...

N. Gagelmann, Christopher R. Reilly, Archana Sasi et al. · 0 citations
Review Open access Oct 2026

T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis

Chimeric antigen receptor T cells and bispecific antibodies, are moving from late-line salvage into early relapsed multiple myeloma. Indirect comparisons in heavily pretreated patients have favored cell therapy, but whether that hierarchy holds in early relapse is unknown. We analyzed randomized phase 3 trials comparin...

Maximilian Merz, J. Souto, P. Voorhees et al. · 0 citations
Open access Sep 2026

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Disease burden at the time of BCMA-directed chimeric antigen receptor (CAR) T-cell infusion is a key determinant of outcome in relapsed or refractory multiple myeloma (RRMM). Bridging therapy is frequently administered between leukapheresis and infusion to prevent disease progression, yet its clinical impact remains un...

M. Wesener, U. Demel, T. Pabst et al. · 0 citations
Open access Sep 2026

iMTSS: an integrated framework for biology- and patient-driven prognosis in myelofibrosis undergoing transplantation.

Relapse and non-relapse mortality after transplantation for myelofibrosis are governed by distinct dimensions, and estimating both outcomes independently with genetic and clinical information, in addition to overall survival, establishes an individualized basis for transplant decision-making.

N. Gagelmann, R. Salit, T. Schroeder et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.